Kuboki, Y., Yaeger, R., Fakih, M. G., Strickler, J. H., Masuishi, T., Kim, E. J., … Hong, D. S. (2022). 315O Sotorasib in combination with panitumumab in refractory KRAS G12C-mutated colorectal cancer: Safety and efficacy for phase Ib full expansion cohort. In Annals of Oncology (Vol. 33, pp. S680–S681). Elsevier BV. https://doi.org/10.1016/j.annonc.2022.07.453

Kuboki, Y., R. Yaeger, M. G. Fakih, J. H. Strickler, T. Masuishi, E. J. Kim, C. M. Bestvina, et al. “315O Sotorasib in combination with panitumumab in refractory KRAS G12C-mutated colorectal cancer: Safety and efficacy for phase Ib full expansion cohort.” In Annals of Oncology, 33:S680–81. Elsevier BV, 2022. https://doi.org/10.1016/j.annonc.2022.07.453.

Kuboki Y, Yaeger R, Fakih MG, Strickler JH, Masuishi T, Kim EJ, et al. 315O Sotorasib in combination with panitumumab in refractory KRAS G12C-mutated colorectal cancer: Safety and efficacy for phase Ib full expansion cohort. In: Annals of Oncology. Elsevier BV; 2022. p. S680–1.

Kuboki, Y., et al. “315O Sotorasib in combination with panitumumab in refractory KRAS G12C-mutated colorectal cancer: Safety and efficacy for phase Ib full expansion cohort.” Annals of Oncology, vol. 33, Elsevier BV, 2022, pp. S680–81. Crossref, doi:10.1016/j.annonc.2022.07.453.

Kuboki Y, Yaeger R, Fakih MG, Strickler JH, Masuishi T, Kim EJ, Bestvina CM, Langer CJ, Krauss JC, Puri S, Cardona P, Chan E, Tran Q, Hong DS. 315O Sotorasib in combination with panitumumab in refractory KRAS G12C-mutated colorectal cancer: Safety and efficacy for phase Ib full expansion cohort. Annals of Oncology. Elsevier BV; 2022. p. S680–S681.